Blab AI
Cosmos Healths Subsidiary CosmoFarm Reports Record $15 Million Q2 Revenue, Expands Pharmacy Network
Cosmos Health Inc. (NASDAQ:COSM) announced on June 18 2026 that its wholly‑owned subsidiary, CosmoFarm S.A., generated more than $15 million in revenue during the second quarter, a figure that translates into an annualized run‑rate exceeding $60 million.
The surge comes as CosmoFarm added over 80 new pharmacies to its distribution network in the quarter, solidifying its standing as a leading wholesaler in the greater Athens area. The move is part of a broader customer‑growth plan that saw the subsidiary’s active pharmacy base climb roughly 20 % in 2025.
To keep pace with the rising volume, Cosmos Health is ramping up capital spending at CosmoFarm. The company will deploy new robotic automation and artificial‑intelligence systems aimed at streamlining procurement, inventory management and order fulfillment. The expansion also includes enlarging the CosmoFarm facility to accommodate higher throughput and continued network growth.
CosmoFarm’s current automated infrastructure already incorporates ROWA and SSI SCHÄFER A‑frame robotic systems. Those platforms have produced measurable gains in operational efficiency, unit economics and profitability per customer, the company noted.
Cosmos Health is a diversified, vertically integrated global healthcare group. Its portfolio features proprietary pharmaceutical and nutraceutical brands such as Sky Premium Life®, Mediterranation®, bio‑bebe®, C‑Sept® and C‑Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices and certified by the European Medicines Agency, the company manufactures pharmaceuticals, food supplements, cosmetics, biocides and medical devices in the EU.
The group also distributes a broad line of pharmaceuticals and parapharmaceuticals—including branded generics and over‑the‑counter medications—to retail pharmacies and wholesale distributors via subsidiaries in Greece and the United Kingdom. In addition, Cosmos Health entered the telehealth market with the acquisition of ZipDoctor, Inc., a Texas‑based provider.
Greg Siokas, CEO of Cosmos Health, described the record quarter as an important milestone. He said the addition of more than 80 new pharmacies reflects the strength of CosmoFarm’s distribution platform and the trust of its growing customer base. Siokas added that the company’s investment in robotic automation, AI and expanded facility capacity will position CosmoFarm to sustain momentum, improve margins and continue scaling profitably.
The announcement arrives as Cosmos Health pursues a global expansion strategy that includes offices and distribution centers in Thessaloniki and Athens, Greece, and Harlow, United Kingdom. The focus on automation and AI in logistics is intended to enhance supply‑chain resilience and cost efficiency across its pharmaceutical, nutraceutical and telehealth businesses.
While the company has not released detailed financial guidance for the rest of 2026, the record revenue and customer growth signal a strengthening market position for CosmoFarm. The continued investment in robotic and AI infrastructure is expected to support further volume increases and potentially improve unit economics for the subsidiary.
Cosmos Health’s broader portfolio—encompassing R&D partnerships targeting obesity, diabetes and cancer, and its focus on AI‑driven drug repurposing—positions the group to leverage cross‑segment synergies. The recent capital allocation to CosmoFarm is part of a wider effort to reinforce supply‑chain capabilities and support long‑term growth objectives.
The company’s latest update does not disclose future product launches, regulatory filings or specific partnership agreements beyond the announced capital expenditures. Investors and industry observers will likely monitor how the expanded automation and AI capabilities translate into operational metrics and whether the increased facility capacity leads to additional revenue growth in subsequent quarters.
The surge comes as CosmoFarm added over 80 new pharmacies to its distribution network in the quarter, solidifying its standing as a leading wholesaler in the greater Athens area. The move is part of a broader customer‑growth plan that saw the subsidiary’s active pharmacy base climb roughly 20 % in 2025.
To keep pace with the rising volume, Cosmos Health is ramping up capital spending at CosmoFarm. The company will deploy new robotic automation and artificial‑intelligence systems aimed at streamlining procurement, inventory management and order fulfillment. The expansion also includes enlarging the CosmoFarm facility to accommodate higher throughput and continued network growth.
CosmoFarm’s current automated infrastructure already incorporates ROWA and SSI SCHÄFER A‑frame robotic systems. Those platforms have produced measurable gains in operational efficiency, unit economics and profitability per customer, the company noted.
Cosmos Health is a diversified, vertically integrated global healthcare group. Its portfolio features proprietary pharmaceutical and nutraceutical brands such as Sky Premium Life®, Mediterranation®, bio‑bebe®, C‑Sept® and C‑Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices and certified by the European Medicines Agency, the company manufactures pharmaceuticals, food supplements, cosmetics, biocides and medical devices in the EU.
The group also distributes a broad line of pharmaceuticals and parapharmaceuticals—including branded generics and over‑the‑counter medications—to retail pharmacies and wholesale distributors via subsidiaries in Greece and the United Kingdom. In addition, Cosmos Health entered the telehealth market with the acquisition of ZipDoctor, Inc., a Texas‑based provider.
Greg Siokas, CEO of Cosmos Health, described the record quarter as an important milestone. He said the addition of more than 80 new pharmacies reflects the strength of CosmoFarm’s distribution platform and the trust of its growing customer base. Siokas added that the company’s investment in robotic automation, AI and expanded facility capacity will position CosmoFarm to sustain momentum, improve margins and continue scaling profitably.
The announcement arrives as Cosmos Health pursues a global expansion strategy that includes offices and distribution centers in Thessaloniki and Athens, Greece, and Harlow, United Kingdom. The focus on automation and AI in logistics is intended to enhance supply‑chain resilience and cost efficiency across its pharmaceutical, nutraceutical and telehealth businesses.
While the company has not released detailed financial guidance for the rest of 2026, the record revenue and customer growth signal a strengthening market position for CosmoFarm. The continued investment in robotic and AI infrastructure is expected to support further volume increases and potentially improve unit economics for the subsidiary.
Cosmos Health’s broader portfolio—encompassing R&D partnerships targeting obesity, diabetes and cancer, and its focus on AI‑driven drug repurposing—positions the group to leverage cross‑segment synergies. The recent capital allocation to CosmoFarm is part of a wider effort to reinforce supply‑chain capabilities and support long‑term growth objectives.
The company’s latest update does not disclose future product launches, regulatory filings or specific partnership agreements beyond the announced capital expenditures. Investors and industry observers will likely monitor how the expanded automation and AI capabilities translate into operational metrics and whether the increased facility capacity leads to additional revenue growth in subsequent quarters.
